ART exposure and clinical characteristics of the HIV+ and HEU subjects.

Results are expressed as median [IQR] (range) unless otherwise indicated. N/A, Not available; n/a, not applicable; IV, intravenous; AZT, zidovudine; 3TC, lamivudine; PI, protease inhibitor; NVP, nevirapine; TDF, tenofovir, FTC, entrabicine, d4T, stavudine, ddI, didanosine, NFV, nelfinavir; T20, fuzeon.aRefers to exposure during pregnancy, labour and delivery.bDuration of exposure missing for 2 HEU.cNot including post-natal prophylaxis.dRefers to longest regimen during pregnancy (± intra-partum IV AZT, single dose NVP), 32 women underwent a regimen change during their pregnancy.eThese consisted of: 3TC+PI+NVP (N = 1); AZT+3TC+EFV (N = 1); ddI+NVP+NFV (N = 1); 3 PI (N = 1); AZT+ABC+3TC (N = 2).fThese consisted of: AZT+3TC+ABC+PI (N = 3); AZT+3TC+TDF+PI (N = 1); AZT+3TC+ddI+PI (N = 1); TDF+FTC+NVP+PI (N = 1); TDF+3TC+T20+PI (N = 1); TDF+3TC+ABC+PI (N = 1).gIncluding post-natal prophylaxis.